Search results

Order by most recent / most popular / relevance

Results: 1-8 of 8

Federal Circuit decides Myriad: holds isolated genomic DNA patentable

Dechert LLP
-
USA
-
July 29 2011

On July 29th, the Federal Circuit handed down its decision in the much-discussed Association for Molecular Pathology v. U.S. Patent and Trademark Office (commonly known as the “Myriad Genetics” case

New chapter in decade long patent fight among DNA diagnostics leaders

Dechert LLP
-
USA
-
February 16 2012

Enzo Life Science’s U.S. Patent No. 6,992,180 entitled “Oligo- or Polynucleotides Comprising Phosphate-Moiety Labeled Nucleotides” (“the ’180 patent”) issued in January of 2006

Supreme Court remands Myriad case in light of Mayo v. Prometheus

Dechert LLP
-
USA
-
March 27 2012

Remember the Myriad case, where a number of Medical Associations and individual doctors assisted by the American Civil Liberties Union and the Public Patent Foundation sued Myriad for a declaration that Myriad’s BRCA diagnostic testing patents were invalid because they were directed to unpatentable subject matter under 101 of the Patent Code?

DNA patenting again at risk before the Federal Circuit

Dechert LLP
-
USA
-
July 23 2012

After an order from the Supreme Court to reconsider the case in light of its decision in Mayo v. Prometheus, a panel of the Federal Circuit Court of Appeals heard arguments in Association for Molecular Pathology v. Myriad Friday

Mayo v. Prometheus limits diagnostic test patenting

Dechert LLP
-
USA
-
March 21 2012

Tuesday the Supreme Court unanimously decided Mayo Collaborative Services v. Prometheus Labs, a decision of considerable significance to the diagnostics industry

Biosimilar developers can breathe a sigh of relief

Dechert LLP
-
USA
-
June 28 2012

With this morning’s Supreme Court affirmance of the bulk of the Affordable Care Act, the specter that the BPCIA framework for biosimilar introduction could be dismantled is no longer a concern

Second Circuit Court of Appeals issues blow against off-label promotion enforcement

Dechert LLP
-
USA
-
December 3 2012

In a split decision today, a panel of the Second Circuit Court of Appeals overturned - on First Amendment grounds - the criminal conviction of a pharmaceutical sales representative who had promoted Jazz Pharmaceutical’s Xyrem for off-label use

Cabilly III: race to the court house

Dechert LLP
-
USA
-
April 21 2011